Board of Trustees of The Leland Stanford Junior University Decreases Stock Position in Bolt Biotherapeutics, Inc. $BOLT

Board of Trustees of The Leland Stanford Junior University lowered its stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 95.0% during the 2nd quarter, Holdings Channel reports. The firm owned 35,978 shares of the company’s stock after selling 683,568 shares during the quarter. Bolt Biotherapeutics makes up about 0.0% of Board of Trustees of The Leland Stanford Junior University’s holdings, making the stock its 19th biggest position. Board of Trustees of The Leland Stanford Junior University’s holdings in Bolt Biotherapeutics were worth $208,000 as of its most recent filing with the Securities & Exchange Commission.

Bolt Biotherapeutics Stock Up 3.9%

BOLT stock opened at $5.83 on Friday. The stock has a market capitalization of $11.19 million, a P/E ratio of -0.22 and a beta of 0.91. The firm has a 50-day simple moving average of $5.40 and a 200-day simple moving average of $5.99. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.56. Bolt Biotherapeutics, Inc. has a 52 week low of $4.59 and a 52 week high of $14.36.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($4.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.40) by $1.94. The business had revenue of $1.80 million for the quarter, compared to analyst estimates of $0.82 million. Equities analysts forecast that Bolt Biotherapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

BOLT has been the topic of several recent research reports. Zacks Research upgraded shares of Bolt Biotherapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Lake Street Capital upped their target price on shares of Bolt Biotherapeutics to $75.00 and gave the stock a “buy” rating in a research note on Friday, August 15th. HC Wainwright set a $7.00 target price on shares of Bolt Biotherapeutics and gave the company a “buy” rating in a research note on Monday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.